

Supplementary Table 5. Network and pairwise meta-analyses for total stroke of antihyperglycemic drugs excluding sotagliflozin

	Placebo	Metformin	Sulfonylurea	TZD	DPP-4 inhibitor	SGLT-2 inhibitor	GLP-1 agonist
Placebo		-	-	2 Studies $I^2=0.0\%$ -0.22 (-0.51 to 0.07)	19 Studies $I^2=0.0\%$ -0.04 (-0.17 to 0.08)	22 Studies $I^2=66.2\%$ -0.23 (-0.55 to 0.08)	13 Studies $I^2=0.00\%$ -0.17 (-0.27 to -0.07)
Metformin	1.01 (0.55 to 1.86)		2 Studies $I^2=19.0\%$ 0.14 (-0.44 to 0.72)	3 Studies $I^2=0.0\%$ -0.23 (-0.88 to 0.41)	2 Studies $I^2=0.0\%$ -1.23 (-3.49 to 1.04)	-	2 Studies $I^2=0.0\%$ -0.40 (-2.33 to 1.52)
Sulfonylurea	1.05 (0.69 to 1.60)	1.04 (0.61 to 1.78)		6 Studies $I^2=0.0\%$ -0.02 (-0.53 to 0.49)	6 Studies $I^2=0.0\%$ -0.15 (-0.41 to 0.11)	-	-
TZD	0.86 (0.57 to 1.30)	0.85 (0.47 to 1.52)	0.82 (0.53 to 1.27)		3 Studies $I^2=0.0\%$ 0.27 (-1.65 to 2.20)	-	1 Study -0.42 (-4.34 to 3.51)
DPP-4 inhibitor	0.93 (0.74 to 1.16)	0.91 (0.50 to 1.67)	0.88 (0.59 to 1.30)	1.08 (0.70 to 1.66)		3 Studies $I^2=0.0\%$ -1.03 (-2.85 to 0.79)	2 Studies $I^2=0.0\%$ -1.25 (-3.73 to 1.24)
SGLT-2 inhibitor	0.81 (0.65 to 0.99)	0.80 (0.42 to 1.51)	0.76 (0.48 to 1.22)	0.94 (0.59 to 1.49)	0.87 (0.64 to 1.18)		-
GLP-1 agonist	0.83 (0.68 to 1.02)	0.82 (0.43 to 1.55)	0.79 (0.50 to 1.25)	0.96 (0.61 to 1.53)	0.90 (0.66 to 1.21)	1.03 (0.77 to 1.38)	

TZD, thiazolidinedione; DPP-4, dipeptidyl peptidase-4; SGLT-2, sodium-glucose cotransporter-2; GLP-1, glucagon-like peptide-1.